Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Inclusion Criteria: * Self-report being diagnosed with atopic dermatitis (AD) by a physician and able to provide approximate diagnosis date. * Autoinjector or Pen naïve \[have not used an autoinjector or pen previously; permissible to have used a pre-filled syringe (PFS) or vial and syringe\]. * Willing and able to attend an in-person interview session. * Able to complete the protocol requirements. Exclusion Criteria: * Cognitive or physical difficulties that could interfere with ability to understand the training, perform the injection tasks, or complete the study questionnaires as judged by the investigator. * Are currently enrolled or have participated in the last 3 months, in a clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. * Is a health care practitioner who is trained in giving injections. * Currently pregnant. * Known hypersensitivity to any component of lebrikizumab or its excipients. * Treatment with a live (or live attenuated) vaccine within the past 12 weeks. * Current or chronic infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) per participant self-report.